XML 21 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues      
Revenues $ 9,625 $ 8,757 $ 8,124
Expenses      
Selling, general and administrative 3,296 2,917 2,625
Research and development 616 604 529
Amortization of intangible assets 1,077 1,077 1,215
Goodwill impairments 0 493 824
Asset impairments 29 54 15
Restructuring, integration, separation and IPO costs 32 62 63
Other expense, net 247 28 35
Total expenses 8,079 7,794 7,670
Operating income 1,546 963 454
Interest income 33 26 14
Interest expense (1,388) (1,328) (1,464)
Gain on extinguishment of debt 23 1 875
Foreign exchange and other (47) (52) (8)
Income (loss) before income taxes 167 (390) (129)
Provision for income taxes (239) (221) (83)
Net loss (72) (611) (212)
Net loss (income) attributable to noncontrolling interest 26 19 (13)
Net loss attributable to Bausch Health Companies Inc. $ (46) $ (592) $ (225)
Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (0.13) $ (1.62) $ (0.62)
Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) $ (0.13) $ (1.62) $ (0.62)
Basic weighted-average common shares (in shares) 368.0 364.9 362.0
Diluted weighted-average common shares (in shares) 368.0 364.9 362.0
Product sales      
Revenues      
Revenues $ 9,518 $ 8,663 $ 8,025
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues 2,729 2,519 2,316
Other revenues      
Revenues      
Revenues 107 94 99
Expenses      
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues $ 53 $ 40 $ 48